Updates from BrightSpring Health Services
- Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib) (Partnership · October 26, 2026)
Onco360 was chosen by AstraZeneca Pharmaceuticals as a national pharmacy partner to provide Zegfrovy (sunvozertinib) for adult patients with specific types of non-small cell lung cancer. - Onco360® Has Been Selected as a National Specialty Pharmacy Partner for BEQALZI™ (sonrotoclax) (Partnership · October 6, 2026)
BeOne Medicines selected Onco360 as a specialty pharmacy partner for Beqalzi (sonrotoclax), a treatment for adults with relapsed or refractory mantle cell lymphoma. - Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant) (Partnership · September 17, 2026)
Onco360 entered a partnership with AstraZeneca to serve as a national pharmacy partner for Etcamah (camizestrant), indicated for certain adult patients with advanced or metastatic breast cancer. - BrightSpring Awards Brighter Futures Scholarship and Hospice Nursing Scholarship to Support Five Students’ Academic Jou… (Culture · May 26, 2026)
BrightSpring Health Services announced the 2026 recipients of the Brighter Futures Scholarship and the Hospice Nursing Scholarship to support students in their academic pursuits.